2,256 research outputs found

    The Impacts of the UK Wine Industry on People, Place and Climate

    Get PDF
    Climate change has moved the boundary at which viniviticulture is possible to above 49.9N+ degrees above latitude, in the UK this has made commercial wine production both possible and profitable. This has triggered a movement in land-use, as vineyards increasingly replace other arable land in England and Wales; a movement of people, as wealthy business professionals return to the land to establish vineyards; and a movement on menus, as English and Welsh wine is stocked at establishments from Weatherspoon’s to The Fat Duck. Concurrently, climate change is severely disrupting agricultural production and livelihoods, prompting passionate calls for a far reaching transformation of the food systems. Agroecology is one potential route to transformation, offering a pathway to an environmental sustainable and social just food system. This paper will explore how the UK wine industry and agroecology have respectively moved from positions of ridicule into a spaces where they are publicly respected. Critically, it will identify if transformative agroecological thinking and practice holds and place in the UK wine industry. This will contribute to the growing body of work that is examining how agroecology appears in practice and what it means in different contexts

    FUEL POVERTY IN IRELAND: EXTENT, AFFECTED GROUPS AND POLICY ISSUES. ESRI WP262. October 2008

    Get PDF
    This paper provides updated estimates for the scale of fuel poverty in the Republic of Ireland using two measures: one based on fuel expenditure as a share of income and the other based on self-reported deprivation. It also presents modeling results as to the characteristics of households most vulnerable to fuel poverty, examines the potential effects of future fuel price changes, outlines policies in place in Ireland and other countries, and discusses policy issues

    National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ?

    Get PDF
    Objectives: The aim was to summarize national prevention of mother-to-child transmission (PMTCT) guidelines across Europe and to identify differences between these. Methods: A survey was conducted using a structured questionnaire sent to experts in 25 European countries from January to March 2012, requesting a copy of the national guidelines. Responses were received from 23 countries. Results: Twenty-two (96%) countries supported a policy to recommend antenatal HIV screening for all pregnant women (15: opt-out strategy; 8: opt-in strategy). For HIV-positive women in whom the only indication for antiretroviral therapy (ART) was PMTCT, the recommended gestational age for commencing ART varied from 12 to 28 weeks: initiation before 19 weeks gestation was recommended in guidelines from nine countries; in France, the UK and the Netherlands, there was a wide range, from 14 to 24 weeks, whereas the Swiss and Ukrainian guidelines recommended starting at 24-28 weeks and the German/Austrian and Lithuanian at 28 weeks. Six national guidelines recommended inclusion of Zidovudine in antenatal ART regimens, and seven (37%) allowed continuation of Efavirenz for women conceiving on this drug. According to nine guidelines, zidovudine should always be used intrapartum. Eighteen national guidelines stated that HIV-positive women on successful ART can have a vaginal delivery. Viral load thresholds for vaginal delivery were <1000 copies/ml in 5 countries, <400 copies/ml in 3 and <50 copies/ml in 11 countries. Conclusion: There are important differences across Europe in national PMTCT guidelines, with most variation seen where the evidence-base remains limited. Such differences should be considered when interpreting research and surveillance finding

    Expressions of Grief in Online Discussion Forums-Linguistic Similarities and Differences in Pet and Human Bereavement

    Get PDF
    We compared online discussion forum posts related to pet loss to those related to human bereavement. Posts (N = 401) were analyzed using the Linguistic Inquiry and Word Count software for frequencies of word use relevant to bereavement. Words related to anger, sadness, and negative emotions were used at similar frequencies for all grief. Sibling loss was associated with using first person pronouns at higher frequencies, and positive emotion words at lower frequencies than other categories of loss. There were some similarities in partners and pets in the word use related to friends and social connectedness. Words related to religion were highest when writing about losing a child and lowest when losing a pet. Our results highlight the similarities in the vocabulary in pet and human bereavement. Findings demonstrate the importance of online discussion forums for understanding the process of grief and specific relationship types

    Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease

    Get PDF
    Background: The UNITI trial reports efficacy of ustekinumab (UST) dose intensification in Crohn's disease (CD) from 12- to 8-weekly, but not 4-weekly. We aimed 1) to assess the cumulative incidence of UST dose intensification to 4- or 6-weekly, 2) to identify factors associated with dose intensification, and 3) to assess the effectiveness of this strategy. Methods: We performed a retrospective, observational cohort study in NHS Lothian including all UST treated CD patients (2015–2020). Results: 163 CD patients were treated with UST (median follow-up: 20.3 months [13.4–38.4]), of whom 55 (33.7%) underwent dose intensification to 4-weekly (n = 50, 30.7%) or 6-weekly (n = 5, 3.1%). After 1 year 29.9% were dose intensified. Prior exposure to both anti-TNF and vedolizumab (HR 9.5; 1.3–70.9), and concomitant steroid use at UST start (HR 1.8; 1.0–3.1) were associated with dose intensification. Following dose intensification, 62.6% patients (29/55) remained on UST beyond 1 year. Corticosteroid-free clinical remission was achieved in 27% at week 16 and 29.6% at last follow-up. Conclusion: One third of CD patients treated with UST underwent dose intensification to a 4- or 6-weekly interval within the first year. Patients who failed both anti-TNF and vedolizumab, or required steroids at initiation were more likely to dose intensify.</p
    • …
    corecore